Mood disorder

The Role of Magnesium in Mental Health: Simple Solutions for Mental Health Month

Retrieved on: 
Tuesday, May 17, 2022

FREMONT, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Just in time for Mental Health Awareness month, researchers at Magceutics LLC have extensively studied the brain and the role of magnesium L-threonate in managing mood disorders.

Key Points: 
  • FREMONT, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Just in time for Mental Health Awareness month, researchers at Magceutics LLC have extensively studied the brain and the role of magnesium L-threonate in managing mood disorders.
  • The first report onmagnesium for improving mood was published in 1921, showing success in 220 out of 250 cases .
  • In recent research, only magnesium L-threonate increased brain magnesium levels, even when compared to magnesium citrate, glycinate, gluconate, malate, and chloride .
  • Magnesium L-threonate proved effective for increasing cerebrospinal fluid magnesium levels compared to magnesium chloride or gluconate,resulting in improved cognition in animal models .

DBSA PEER SPECIALIST INSTRUCTOR AND MILITARY VETERAN PROVIDES TESTIMONY IN SUPPORT OF PENDING LEGISLATION FOR THE VIRTUAL PEER SUPPORT ACT

Retrieved on: 
Tuesday, April 5, 2022

(CHICAGO) LeVail Smith, Peer Specialist and instructor for the Depression and Bipolar Support Alliance (DBSA ), spoke Tuesday as a panelist at the Energy and Commerce Health Subcommittee hearing in support of pending legislation H.R.

Key Points: 
  • (CHICAGO) LeVail Smith, Peer Specialist and instructor for the Depression and Bipolar Support Alliance (DBSA ), spoke Tuesday as a panelist at the Energy and Commerce Health Subcommittee hearing in support of pending legislation H.R.
  • As an instructor for the DBSA Peer Support Specialist course and a mentor for other peers participating in the DBSA peer apprentice program, Smith shared his experiences as an individual in recovery and wellness living with a mental health issue and substance use condition.
  • 2929, the Virtual Peer Support Act that, if it becomes law, will provide funding to expand access to virtual peer support services, including virtual support group meetings, and provide training to individuals who want to become state-certified peer support specialists.
  • We have seen the demand for DBSA virtual support groups jump by more than 137% since the start of the pandemic, said Michael Pollock, CEO of DBSA.

Joint Statement from the Co-Chairs of the Special Advisory Committee on the Epidemic of Opioid Overdoses - Latest National Data on the Overdose Crisis

Retrieved on: 
Wednesday, March 23, 2022

OTTAWA, ON, March 23, 2022 /CNW/ - Today, the co-chairs of the federal, provincial and territorial Special Advisory Committee on the Epidemic of Opioid OverdosesDr.

Key Points: 
  • OTTAWA, ON, March 23, 2022 /CNW/ - Today, the co-chairs of the federal, provincial and territorial Special Advisory Committee on the Epidemic of Opioid OverdosesDr.
  • Canada's worsening overdose crisis continues to be exacerbated by the challenges of the COVID-19 pandemic.
  • The latest data show that the number of opioid-related deaths remained high and opioid-related hospitalizations increased from January to September 2021.
  • The Special Advisory Committee will continue to encourage and support the improvement of data and analysis to inform these strategies and interventions.

Depressive disorder may hinder healing in patients undergoing reverse shoulder arthroplasty

Retrieved on: 
Tuesday, March 22, 2022

CHICAGO, March 22, 2022 /PRNewswire/ -- Depressive disorder (DD) is associated with longer in-hospital length of stay (LOS), higher rates of medical complications, and increased healthcare costs for patients undergoing reverse shoulder arthroplasty (RSA) for the treatment of glenohumeral osteoarthritis (OA), according to a large-scale study presented at the 2022 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS). While current studies have shown DD to be linked to higher complications following shoulder arthroplasty, the effects of depression on primary RSA have not been studied as extensively.

Key Points: 
  • Studies have shown that DD can lead to poor health, mortality, and substance abuse, and there is an established link between DD and negative outcomes for patients undergoing shoulder arthroplasty.
  • OA is the most common form of arthritis to affect the shoulder, commonly referred to as glenohumeral OA or shoulder OA.
  • From 1993 to 2007, there was a 248% increase, with RSA accounting for 42% of total shoulder arthroplasty procedures performed during that timeframe.
  • Significantly higher costs of care were associated with patients who were in the depressive disorder group ($19,363.10 vs. $17,927.55).

Sage Therapeutics and Biogen Announce the Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints - Comparing Zuranolone 50 mg Co-initiated with Standard of Care Antidepressant vs. Standard of Care Co-initiated with Placebo in People with MDD

Retrieved on: 
Wednesday, February 16, 2022

The CORAL Study (217-MDD-305) was a Phase 3, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of zuranolone 50 mg co-initiated with an open-label standard of care antidepressant (ADT) compared to a standard of care ADT co-initiated with placebo in adults with MDD.

Key Points: 
  • The CORAL Study (217-MDD-305) was a Phase 3, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of zuranolone 50 mg co-initiated with an open-label standard of care antidepressant (ADT) compared to a standard of care ADT co-initiated with placebo in adults with MDD.
  • People in the study were randomized to receive zuranolone 50 mg with a standard of care ADT or a standard of care ADT co-initiated with placebo once nightly for two weeks.
  • The primary endpoint was the change in baseline 17-item Hamilton Rating Scale for Depression (HAMD-17) total score at Day 3.
  • The LANDSCAPE program includes five studies of zuranolone in people with MDD (MDD-201B, MOUNTAIN, SHORELINE, WATERFALL, and CORAL Studies).

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Retrieved on: 
Thursday, February 17, 2022

Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.

Key Points: 
  • Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.
  • Up to 40% of cancer patients meet the criteria for a mood disorder requiring treatment2.
  • The EVM-101 study will directly assess the core features of CRD that are most affected and amenable to improvement following a psilocybin-based treatment.
  • Patient enrollment in the clinical trial is expected to begin late in 2022 or early in 2023.

LIGHTFULLY BEHAVIORAL HEALTH LAUNCHES TWO OF 13 PRIMARY MENTAL HEALTH FACILITIES IN CALIFORNIA

Retrieved on: 
Tuesday, February 15, 2022

LOS ANGELES, Feb. 15, 2022 /PRNewswire/ -- Health care startup Lightfully Behavioral Health has acquired Resilience Treatment Center for Mental Health in West Los Angeles, securing two of 13 mental health treatment centers it plans to open in California in the upcoming year.

Key Points: 
  • LOS ANGELES, Feb. 15, 2022 /PRNewswire/ -- Health care startup Lightfully Behavioral Health has acquired Resilience Treatment Center for Mental Health in West Los Angeles, securing two of 13 mental health treatment centers it plans to open in California in the upcoming year.
  • Lightfully was founded by health care veteran executive Jennifer Steiner and four other female industry experts with more than 70 years of combined experience launching and scaling mental health businesses.
  • "Most of the mental health care services were focused on chemical dependency or eating disorders, not primary mental health conditions.
  • Lightfully Behavioral Health is a leader in primary mental health treatment providing high-quality, evidenced-based programming with a full continuum of services to meet the needs of commercially insured clients.

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Retrieved on: 
Thursday, January 6, 2022

Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.

Key Points: 
  • Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.
  • The results of this survey do not necessarily represent the experiences of the broader population of people living with BD-I.
  • Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability to function.
  • Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication.

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Retrieved on: 
Thursday, January 6, 2022

DUBLIN, Jan. 6, 2022 /PRNewswire/ -- Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of living with this serious mental health condition and their experiences with treatment. This research was conducted in support of Alkermes' commitment to understanding the unique needs of people living with BD-I and supporting increased disease awareness and education. 

Key Points: 
  • Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.
  • The results of this survey do not necessarily represent the experiences of the broader population of people living with BD-I.
  • Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability to function.
  • Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication.

ieso Raises $53m to Address Global Mental Health Crisis With Digital Therapeutics

Retrieved on: 
Tuesday, November 23, 2021

The growth in wellness and mental health apps aims to meet this demand, but there is currently a lack of clinically-evidenced digital therapeutics for treating diagnosed mental health conditions.

Key Points: 
  • The growth in wellness and mental health apps aims to meet this demand, but there is currently a lack of clinically-evidenced digital therapeutics for treating diagnosed mental health conditions.
  • The funds raised will help ieso address this global mental health crisis by developing autonomous therapy systems that match the high standards of human care delivery, at significantly lower cost to health systems.
  • Commenting on the successful Series B financing, Nigel Pitchford, CEO of ieso, said: At ieso, were looking to transform global mental health by unlocking the power of clinical data to develop AI-enabled digital therapeutics.
  • It is addressing the global mental health crisis by developing clinically evidenced assessment and treatment products that enable everyone with a common mental health condition to recover.